Association of epicardial adipose tissue thickness and inflammation parameters with CHA2DS2-VASc score in patients with nonvalvular atrial fibrillation
Received 22 August 2015
Accepted for publication 14 October 2015
Published 6 November 2015 Volume 2015:11 Pages 1675—1681
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Garry Walsh
Serkan Akdag, Hakki Simsek, Musa Sahin, Aytac Akyol, Ramazan Duz, Naci Babat
Department of Cardiology, Yuzuncu Yil University Medical Faculty, Van, Turkey
Background: Epicardial adipose tissue (EAT), mean platelet volume (MPV), platelet-to-
lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR) have been shown to be helpful in predicting adverse cardiovascular events. However, to date, in the literature, there have been no studies demonstrating the relationship between EAT, MPV, PLR, NLR, and thromboembolism risk in atrial fibrillation (AF). Therefore, we examined the relationship between EAT, MPV, PLR, NLR, and CHA2DS2-VASc score used for the evaluation of thromboembolism risk in patients with AF.
Methods: The study included 96 consecutive patients with AF and 52 age- and sex-matched control subjects. We calculated CHA2DS2-VASc risk score for each patient and measured baseline EAT thickness, MPV, PLR, NLR, left atrial volume index, and left ventricular ejection fraction.
Results: The group with high CHA2DS2-VASc score had higher EAT (7.2±1.5 vs 5.9±1.2 mm, P<0.001), MPV (9.1±1.1 vs 8.4±1.0 fL, P=0.004), PLR (152.3±28.4 vs 126.7±25.4, P=0.001), and NLR (4.0±1.6 vs 3.2±1.3, P<0.001) compared to group with low-intermediate CHA2DS2-VASc score. Moreover, CHA2DS2-VASc score was found to be positively correlated with EAT (r=0.623, P<0.001), MPV (r=0.350, P=0.004), PLR (r=0.398, P=0.001), and NLR (r=0.518, P<0.001).
Conclusion: Our study results demonstrated that EAT thickness, MPV, PLR, and NLR were associated with the thromboembolic risk exhibited by CHA2DS2-VASc score in patients with nonvalvular AF.
Keywords: atrial fibrillation, epicardial adipose tissue, platelet, neutrophil, mean platelet volume
Nonvalvular atrial fibrillation (AF) is the most frequently sustained arrhythmia in clinical practice and presents a high risk of thromboembolism.1 Numerous scoring systems have been used in the stratification of thromboembolism risk in AF patients.2 Of these, CHA2DS2-VASc is the most commonly suggested system. All the components of this system have been demonstrated to be associated with increased incidence of thromboembolism in patients with AF.3 The genesis of AF is of a multifactorial nature, but the study has shown that inflammation plays a key role in the initiation and progression of AF.4
Epicardial adipose tissue (EAT) functions as an active endocrine organ and has been demonstrated to be a significant source of inflammatory mediators and to play a major role in the pathophysiology of AF since it is located close to the heart.5 Mean platelet volume (MPV), a measure of platelet activation and function, is a potential mediator of the relationship between inflammation and thrombosis.6 MPV is higher in patients with AF compared to that in patients with sinus rhythm.7 Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have recently been used as systemic inflammatory markers and prognostic indicators of adverse cardiovascular events.8,9 NLR is also used for predicting the left atrial (LA) thrombus in patients with nonvalvular AF.10
The aim of this study was to investigate the association between EAT thickness, MPV, NLR, PLR, and the CHA2DS2-VASc score used for the stratification of thromboembolism risk in patients with nonvalvular AF.
Materials and methods
The study was performed in compliance with the Declaration of Helsinki, and the study protocol was approved by the Yuzuncu Yil University, Faculty of Medicine Ethics Committee. The participants’ written informed consent was also obtained. The cross-sectional observational study included a total of 96 consecutive patients who presented to the outpatient clinics of our university hospital with nonvalvular AF and 52 age- and sex-matched control subjects. The inclusion criteria were patients over 18 years of age who presented to the cardiology clinic with at least one attack of AF diagnosed by electrocardiographic examination and assessed by a cardiologist. Exclusion criteria included autoimmune disease, significant congestive heart failure, renal or hepatic disease, clinically significant valvular heart disease, cancer, ongoing infection or systemic inflammatory conditions, comorbidities, and patients with poor echocardiographic windows.
A complete physical examination was performed in all the patients. Also, the medical histories and clinical features of the patients were recorded. AF was defined as the absence of P waves on electrocardiography and irregular R–R interval. The types of AF were defined in accordance with the European Society of Cardiology guidelines. According to these guidelines, a patient detected with AF for the first time is considered a patient with first diagnosed AF, regardless of the duration of arrhythmia or the presence and severity of AF-related symptoms. Paroxysmal AF is generally self-terminating and continues for up to 7 days. In persistent AF, the episode either lasts for >7 days or requires termination by cardioversion, either by medication or direct current cardioversion. In long-standing persistent AF, the episode lasts for ≥1 year, and a rhythm control strategy is adopted. On the other hand, if the patient presents with long-standing AF, in whom cardioversion has failed or has not been tried, the patient is considered to have permanent AF. In this study, we used the CHA2DS2-VASc scoring system, which is used to stratify the risk of long-term thromboembolic events related to AF (Table 1). Depending on this system, the AF patients were divided into two groups: 1) low-intermediate risk group and 2) high-risk group. Accordingly, a score of “0” was regarded as low risk, “1” as intermediate risk, and “≥2” as high risk.
Table 1 CHA2DS2-VASc score
Each patient underwent transthoracic two-dimensional echocardiography at rest under standard procedures. The patient was placed in the left lateral decubitus position, and a commercial echocardiographic device (Vivid 3, General Electric, Chicago, IL, USA) with a 3.0 MHz transducer was used for the examination. The examinations were performed by two experienced cardiologists blinded to the study. In order to avoid interreader variability, the offline assessments of the EAT thickness were performed by two cardiologists blinded to the patient data. In order to assess the inter- and intraobserver variability, the echocardiograms of 30 patients were randomly selected and a second measurement of the EAT thickness was performed 2 weeks later. The inter- and intraobserver variability of the EAT thickness were 3.2% and 2.6%, respectively. The diameter of the left atrium was measured at end-systole in the parasternal long-axis view using the standard criteria. Left ventricular ejection fraction (LVEF) was also calculated. The epicardial fat was identified as an echo-free space in the pericardial layers on the two-dimensional echocardiography. By using the Simpson’s method, the maximum EAT thickness was measured at the point on the free wall of the right ventricle along the midline of the ultrasound beam, perpendicular to the aortic annulus, which is used as the anatomic landmark at end-systole in three cardiac cycles.
Biochemical and hematological measurements
Blood sample was collected from the antecubital vein using a 21-gauge sterile syringe without stasis between 8 and 10 am, following a 12-hour fasting period. To assess complete blood count, a Coulter LH 780 Hematology Analyzer (Architect plus ci16200, Abbott, Lake Forest, IL, USA) was used for measuring the hematological parameters including platelet counts, neutrophil counts, lymphocyte counts, and MPV. Baseline NLR was measured by dividing neutrophil count by lymphocyte count. Baseline PLR was measured by dividing platelet count by lymphocyte count.
All the statistical data were analyzed using SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Continuous data were expressed as mean ± standard deviation, and the categorical data were expressed as percentage. When necessary, the Pearson’s or the Spearman’s correlation coefficient was performed to analyze the correlation between the variables. Statistical comparisons were performed using one-way analysis of variance, followed by Scheffé’s test. A P-value of <0.05 was considered significant.
A total of 148 patients (96 patients with nonvalvular AF and 52 control subjects) were included in the present study. Baseline demographic, clinical, and laboratory characteristics of the nonvalvular AF and the control groups are presented in Table 2. The median CHA2DS2-VASc score was 2, and 53.1% of the patients were in the high CHA2DS2-VASc group. Within the nonvalvular AF group, there were 51 patients with high CHA2DS2-VASc score and 45 patients with low-intermediate CHA2DS2-VASc score. Of all the patients, 22.9% of the cases had paroxysmal, 16.7% had persistent, and 60.4% had permanent AF. Other baseline characteristics and previous medications are shown in Table 3. Patients with nonvalvular AF had significantly higher EAT (6.6±1.3 vs 4.9±1.0 mm, P<0.001), MPV (8.9±1.1 vs 7.8±1.0 fL, P<0.001), PLR (140.3±24.2 vs 119.3±21.9, P=0.002), and NLR (3.6±1.5 vs 2.9±1.3, P<0.001) compared to the control subjects. LA volume index (P<0.001) was significantly higher in the nonvalvular AF group compared to the controls. However, LVEF (P<0.001) was significantly lower in the nonvalvular AF group compared to the controls (Table 2). High CHA2DS2-VASc group had higher EAT (7.2±1.5 vs 5.9±1.2 mm, P<0.001), MPV (9.1±1.1 vs 8.4±1.0 fL, P=0.004), PLR (152.3±28.4 vs 126.7±25.4, P=0.001), and NLR (4.0±1.6 vs 3.2±1.3, P<0.001) compared to the low-intermediate CHA2DS2-VASc group. Moreover, age (P<0.001), LA volume index (P<0.001), hypertension (P<0.001), and diabetes (P=0.006) were significantly higher in the high CHA2DS2-VASc group compared to the low-intermediate CHA2DS2-VASc group. However, LVEF (P<0.001) was significantly lower in the high CHA2DS2-VASc group compared to the low-intermediate CHA2DS2-VASc group (Table 3). Moreover, CHA2DS2-VASc score was found to be positively correlated with EAT (r=0.623, P<0.001) (Figure 1), MPV (r=0.350, P=0.004) (Figure 2), PLR (r=0.398, P=0.001) (Figure 3), and NLR (r=0.518, P<0.001) (Figure 4).
Figure 1 Correlation plots between echocardiographic EAT thickness and CHA2DS2-VASc score.
Figure 2 Correlation plots between MPV and CHA2DS2-VASc score.
Figure 3 Correlation plots between PLR and CHA2DS2-VASc score.
Figure 4 Correlation plots between NLR and CHA2DS2-VASc score.
There were three main findings of the present study. First, EAT thickness was found to be higher in the nonvalvular AF group compared to the control group. Second, inflammation markers including MPV, PLR, and NLR were significantly elevated in the nonvalvular AF group. Third, EAT thickness, MPV, PLR, and NLR were correlated with the CHA2DS2-VASc score in patients with nonvalvular AF, which were also independent predictors of high CHA2DS2-VASc score.
Nonvalvular AF is the most frequently sustained arrhythmia in clinical practice and presents a high risk of stroke and thromboembolism.1 The incidence of thromboembolism may vary according to the coexisting clinical, echocardiographic, and biochemical factors in AF patients. Therefore, numerous scoring systems have been developed for the stratification of thromboembolism risk in AF patients.2 Of these systems, the CHA2DS2-VASc score is the most commonly suggested system.11 This system categories the thromboembolism risk in AF patients into two levels: low risk and high risk. Accordingly, patients with high risk have a higher incidence of thromboembolic events.
In addition to the effects of well-known cardiovascular risk factors on the initiation and progression of AF, researchers have recently aimed at evaluating the role of inflammation on the progression of AF.12 EAT has been shown to be effective on the progression of both coronary atherosclerosis and cardiac arrhythmia.13 EAT is a true visceral fat deposited around the heart, particularly around the subepicardial coronary vessels. It has been demonstrated that EAT functions as an active endocrine organ, which generates several proinflammatory and proatherogenic cytokines and bioactive adipokines.14 EAT thickness has recently emerged as a novel risk factor for cardiovascular disease in the general population.14 A previous study has reported the autocrine and paracrine effects of EAT on cardiac physiology.15 Moreover, a study also investigated the relationship between EAT thickness assessed by various methods and found a positive correlation between EAT thickness and AF.13 Recently, Shin et al16 also reported that computed tomography-measured epicardial fat volumes established a significant correlation with the presence and progression of AF. In addition, a relationship between the epicardial fat and long-term clinical outcomes following AF ablation has also been reported. Similarly, Nagashima et al17 also reported greater epicardial fat volumes in patients with AF recurrence after radiofrequency ablation. In another study, the same authors reported a correlation between the dominant frequency sites and the epicardial fat locations. They also reported higher epicardial fat volumes and higher levels of serum inflammatory markers in patients with persistent AF when compared to the patients with paroxysmal AF.18 Recently, EAT thickness as assessed by echocardiography has emerged as a practical method for the evaluation of the cardiometabolic risk and the risk of visceral adiposity. In this study, EAT thickness was measured using echocardiography, and a positive correlation was found between the CHA2DS2-VASc score and epicardial fat in the nonvalvular AF group.
MPV, PLR, and NLR, which are the parameters measured in routine blood samples, are inflammatory markers of cardiovascular disease.6–9 MPV is a measure of platelet size and is regarded as a marker and determinant of platelet function since the platelets with larger sizes are hemostatically more reactive than the platelets with normal sizes, thus increasing the predisposition to thrombosis and resulting in acute coronary syndromes or ischemic stroke.19,20 A study reported that the MPV level was higher in AF patients compared to subjects in sinus rhythm.21 Additionally, Ha et al19 reported that MPV functions as a predictive marker of stroke in AF patients. In the same study, MPV was found to add incremental predictive value to the clinical variables involved in the CHADS2 score. Very recently, a case–control study reported that stroke patients with AF exhibited higher MPV levels than those exhibited by AF patients with no history of stroke.22 In our study, the MPV levels were higher in the nonvalvular AF group and correlation was established between the MPV levels and CHA2DS2-VASc score.
PLR and NLR have recently been used as significant inflammatory markers and novel predictors of major adverse outcomes in cardiovascular disease.8,9 Recent studies have also shown that high platelet count and low lymphocyte count have a close relationship with the poor prognosis in patients with coronary artery disease.23–25 Azab et al24 reported that elevated PLR was an independent predictor for long-term mortality in patients with non-ST elevation myocardial infarction. Akkaya et al25 found that PLR has a significant role in the increase in adverse clinical outcomes and mortality within the 6 months after percutaneous coronary intervention in patients with ST elevation myocardial infarction.
Increased PLR and NLR are associated with the severity of coronary atherosclerosis in patients with coronary artery disease and congestive heart failure.9,26 A study reported that increased NLR was associated with higher inpatient mortality in patients with advanced heart failure.26 Another study found that NLR levels were associated with the increased risk of ventricular arrhythmias during percutaneous coronary intervention.8 Moreover, NLR has recently emerged as a risk marker for AF progression following coronary artery bypass grafting and as a predictor for early recurrence of AF following radiofrequency catheter ablation.27,28 Also, elevated NLR has been shown to increase the risk of thromboembolic stroke in patients with nonvalvular AF.29 In our study, PLR and NLR levels were higher in the nonvalvular AF group and a positive correlation was established between CHA2DS2-VASc score.
Stratification of the thromboembolism risk is of prime importance for the prevention of adverse outcomes in patients with nonvalvular AF. We propose that EAT thickness, MPV, NLR, and PLR, which can be measured by an inexpensive and simple method, may be significant predictors of the thromboembolism risk in patients with nonvalvular AF.
Our study is limited since it had a relatively small number of patients. Echocardiographic EAT thickness is a linear measurement, and thus it may not assess the total epicardial fat volume that varies at various myocardial locations. Moreover, other cytokines or inflammatory markers were not evaluated and not compared with MPV, NLR, and PLR.
To our knowledge, this is the first study to determine the association of EAT thickness, MPV, PLR, and NLR with CHA2DS2-VASc score in patients with nonvalvular AF. The study revealed that EAT thickness, MPV, PLR, and NLR were associated with the thromboembolic risk exhibited by CHA2DS2-VASc score in patients with nonvalvular AF. On the other hand, it is of interest that we can infer from this article that there is a certain correlation between inflammatory markers and CHA2DS2-VASc scores, suggesting that anti-inflammatory therapy may be beneficial in reducing risk factors in AF patients. Moreover, these parameters may be beneficial in the stratification of the thromboembolic risk. However, further large-scale studies are needed in this regard.
The authors report no conflicts of interest in this work.
Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108(6):711–716.
Chamberlain AM, Agarwal SK, Folsom AR, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011;107(1):85–91.
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–272.
Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27(2):136–149.
Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham heart study. Circulation. 2008;117:605–613.
Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011;17:47–58.
Colkesen Y, Acil T, Abayli B, et al. Mean platelet volume is elevated during paroxysmal atrial fibrillation: a marker of increased platelet activation. Blood Coagul Fibrinolysis. 2008;19:411–414.
Chatterjee S, Chandra P, Guha G, et al. Pre-procedural elevated white blood cell count and neutrophil-lymphocyte (N/L) ratio are predictors of ventricular arrhythmias during percutaneous coronary intervention. Cardiovasc Hematol Disord Drug Targets. 2011;11(2):58–60.
Yuksel M, Yildiz A, Oylumlu M, et al. Platelet/lenfosit orani ile koroner arter hastaliğinin ciddiyeti arasindaki ilişki [The association between platelet/lymphocyte ratio and coronary artery disease severity]. Anadolu Kardiyol Derg. 2015;15(8):640–647. doi:10.5152/akd. 2014.5565. Turkish.
Yalcin M, Aparci M, Uz O, et al. Neutrophil–lymphocyte ratio may predict left atrial thrombus in patients with nonvalvular atrial fibrillation. Clin Appl Thromb Hemost. 2015;21(2):166–171.
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719–2747.
Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol Med. 2011;17:556–563.
Girerd N, Scridon A, Bessiere F, et al. Periatrial epicardial fat is associated with markers of endothelial dysfunction in patients with atrial fibrillation. PLoS One. 2013;8:e77167.
Mahabadi AA, Berg MH, Lehmann N, et al. Association of epicardial fat with cardiovascular risk factors and incident myocardial infarction in the general population: the Heinz Nixdorf Recall Study. J Am Coll Cardiol. 2013;61:1388–1395.
Lin YK, Chen YJ, Chen SA. Potential atrial arrhythmogenicity of adipocytes: implications for the genesis of atrial fibrillation. Med Hypotheses. 2011;74:1026–1029.
Shin SY, Yong HS, Lim HE, et al. Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:647–655.
Nagashima K, Okumura Y, Watanabe I, et al. Association between epicardial adipose tissue volumes on 3-dimensional reconstructed CT images and recurrence of atrial fibrillation after catheter ablation. Circ J. 2011;75:2559–2565.
Nagashima K, Okumura Y, Watanabe I, et al. Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ Arrhythm Electrophysiol. 2012;5:676–683.
Ha SI, Choi DH, Ki YJ, et al. Stroke prediction using mean platelet volume in patients with atrial fibrillation. Platelets. 2011;22: 408–414.
Mathur A, Robinson MS, Cotton J, Martin JF, Erusalimsky JD. Platelet reactivity in acute coronary syndromes: evidence for differences in platelet behaviour between unstable angina and myocardial infarction. Thromb Haemost. 2001;85:989–994.
Yuce M, Cakici M, Davutoglu V, et al. Relationship between mean platelet volume and atrial thrombus in patients with atrial fibrillation. Blood Coagul Fibrinolysis. 2010;21:722–725.
Turfan M, Erdogan E, Ertas G, et al. Usefulness of mean platelet volume for predicting stroke risk in atrial fibrillation patients. Blood Coagul Fibrinolysis. 2013;24(1):55–58.
Yilmaz S, Sen F, Unal S, et al. Usefulness of the platelet-to-lymphocyte ratio to predict bare metal stent restenosis. Scand Cardiovasc J. 2015;49(1):39–44.
Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34(3):326–334.
Akkaya E, Gul M, Ugur M. Platelet to lymphocyte ratio: a simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol. 2014;177(2):597–598.
Uthamalingam S, Patvardhan EA, Subramanian S, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol. 2011;107:433–438.
Gibson PH, Cuthbertson BH, Croal BL, et al. Usefulness of neutrophil/lymphocyte ratio as predictor of new-onset atrial fibrillation after coronary artery bypass grafting. Am J Cardiol. 2010;105:186–191.
Im SI, Shin SY, Na JO, et al. Usefulness of neutrophil/lymphocyte ratio in predicting early recurrence after radiofrequency catheter ablation in patients with atrial fibrillation. Int J Cardiol. 2013;168:4398–4400.
Ertas G, Sonmez O, Turfan M, et al. Neutrophil/lymphocyte ratio is associated with thromboembolic stroke in patients with non-valvular atrial fibrillation. J Neurol Sci. 2013;324:49–52.
© 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.